Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Midcap Financial
AddedFeb 13, 2024
UpdatedJun 28, 2026
Midcap Financial

Midcap Financial

Acquired

MidCap Financial, a specialty finance firm managed by Apollo Capital, provides flexible, cost-effective senior debt solutions to diverse industries.

Location
Bethesda, MD, US
Founded
2008
Firm
Compare
Portfolio
Fundraising
Employees
Website

Investments

Strata Skin Sciences
Strata Skin Sciences
Public

Total Raised

$29.5M

Rounds

4

Post Ipo Debt$12MJuly 2023
Marco
Marco

Total Raised

$326.4M

Rounds

8

Debt Financing$200MFebruary 2023
Apyx Medical
Apyx Medical
Public

Total Raised

$160.5M

Rounds

7

Post Ipo Debt$10MFebruary 2023
ViewRay
ViewRay
Public

Total Raised

$877.8M

Rounds

22

Post Ipo Debt$125MNovember 2022
Tela Bio
Tela Bio
Public

Total Raised

$230.4M

Rounds

12

Post Ipo Debt$50MMay 2022
Forge Biologics
Forge Biologics

Total Raised

$330M

Rounds

5

Debt Financing$80MJanuary 2022
Aterian
Aterian
Public

Total Raised

$70M

Rounds

5

Post Ipo Debt$50MDecember 2021
Upstack
Upstack

Total Raised

$186.8M

Rounds

4

Late Stage Private$100MNovember 2021
Unchained Labs
Unchained Labs

Total Raised

$285M

Rounds

6

Debt Financing$155MAugust 2021
Xtant Medical Holdings
Xtant Medical Holdings
Public

Total Raised

$191.6M

Rounds

9

Post Ipo Debt$20MMay 2021
LendingPoint
LendingPoint

Total Raised

$1.9B

Rounds

10

Debt Financing$110MMarch 2021
Arboretum Investment Advisors
Arboretum Investment Advisors

Total Raised

$25M

Rounds

1

Debt Financing$25MDecember 2019
Sight Sciences
Sight Sciences
Public

Total Raised

$173.7M

Rounds

9

Series D$31MSeptember 2019
BioCryst Pharmaceuticals
BioCryst Pharmaceuticals
Public

Total Raised

$1.8B

Rounds

19

Post Ipo Debt$100MFebruary 2019
Post Ipo Debt$23MSeptember 2016
Kashable
Kashable

Total Raised

$185.6M

Rounds

5

Debt Financing$100MOctober 2018
The Credit Junction
The Credit Junction

Total Raised

$225M

Rounds

4

Debt Financing$150MApril 2018
ZPower
ZPower

Total Raised

$150.4M

Rounds

7

Series B$25MFebruary 2018
Partner Therapeutics
Partner Therapeutics
Public

Total Raised

$60M

Rounds

1

Series A$60MFebruary 2018
Dnanexus
Dnanexus

Total Raised

$472.6M

Rounds

9

Series E$58MJanuary 2018
Sarepta Therapeutics
Sarepta Therapeutics
Public

Total Raised

$1.4B

Rounds

8

Post Ipo Debt$100MJuly 2017
Elutia
Elutia
Public

Total Raised

$69.8M

Rounds

9

Series Unknown$12MJune 2017
Fundation Group
Fundation Group

Total Raised

$257.7M

Rounds

6

Debt Financing$35MMarch 2017
Intarcia Therapeutics
Intarcia Therapeutics

Total Raised

$1.7B

Rounds

23

Debt Financing$75MMay 2016
Spectra7 Microsystems
Spectra7 Microsystems
Public

Total Raised

$89.3M

Rounds

16

Post Ipo Debt$6.5MMarch 2016